Saroglitazar for the treatment of dyslipidemia in diabetic patients

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 4, 2015, Pages 597-606

  Joshi, Shashank R ^a  

^a LILAVATI HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

Diabetes; Dyslipidemia; PPAR; Saroglitazar; Triglycerides

Indexed keywords

ALKALINE PHOSPHATASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; SAROGLITAZAR; THYROTROPIN; TRIACYLGLYCEROL; ALPHA-ETHOXY-4-(2-(2-METHYL-5-(4-METHYLTHIO)PHENYL))-1H-PYRROL-1-YL)ETHOXY))BENZENEPROPANOIC ACID; GLUCOSE BLOOD LEVEL; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLPROPIONIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; ECG ABNORMALITY; ECHOCARDIOGRAPHY; FEVER; GASTRITIS; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HALF LIFE TIME; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FUNCTION; LIPODYSTROPHY; MAXIMUM PLASMA CONCENTRATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PAIN; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; UREA NITROGEN BLOOD LEVEL; WEIGHT GAIN; AGONISTS; ANIMAL; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DYSLIPIDEMIAS; GLUCOSE BLOOD LEVEL; RISK FACTOR;

ANIMALS; ATHEROSCLEROSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; PHENYLPROPIONATES; PPAR ALPHA; PPAR GAMMA; PYRROLES; RISK FACTORS;

EID: 84922855461     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1009894     Document Type: Review

References (64)

1. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard School of Public Health, Boston; 1996
2. Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases, part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-53
3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52
4. Wild SH, Byrne CD, Tzoulaki I, et al. Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: the Edinburgh Artery Study. Atherosclerosis 2009;203(2):604-9
5. Rodriguez-Colon SM, Mo J, Duan Y, et al. Metabolic syndrome clusters and the risk of incident stroke: the atherosclerosis risk in communities (ARIC) study. Stroke 2009;40(1):200-5
6. Joshi SR, Anjana RM, Deepa M, et al. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB Study. PLoS One 2014;9(5):e96808
7. Parikh RM, Joshi SR, Menon PS, Shah NS. Diabetes & Metabolic Syndrome: Clinical Research 4(1):10-12
8. Murad MH, Hazem A, Coto-Yglesias F, et al. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord 2012;12:2
9. Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011;28:1343-51
10. Feher M, Greener M, Munro N. Persistent hypertriglyceridemia in statintreated patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2013;6:11-15
11. Harchaoui KEL, Visser ME, Kastelein JJP, et al. Triglycerides and cardiovascular risk. Curr Cardiol Rev 2009;5(3):216-22
12. Jeppesen J, Ole Hein H, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36
13. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011;9:258-70
14. Reiner Z, Catapano AL, Backer GD, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
15. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99(6A):3C-18C
16. Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. Eur J Clin Invest 2013;43(5):522-31
17. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS,. Fibrate- Associated Adverse Effects Beyond Muscle and Liver Toxicity. Curr Pharm Des 2008;14(6):574-87
18. AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255-67
19. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebocontrolled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17):1279-91
20. Mozaffarian D, Wu JH. Omega-3 fatty acids and CVD: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047-67
21. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (amr101) therapy in patients with very high triglyceride levels (from the Multicenter, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial). Am J Cardiol 2011;108:682-90
22. The ORIGIN Trial Investigators. Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18
23. Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771(8):1065-81
24. Escher P, Braissant O, Basu-Modak S, et al. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001;142(10):4195-202
25. Chang F, Jaber LA, Berlie HD, O'Connell MB. Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 2007;41(6):973-83
26. Feige JN, Gelman L, Michalik L, et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006;45(2):120-59
27. Balakumar P, Rose M, Ganti SS, et al. PPAR dual agonists: are they opening pandora's box?. Pharmacol Res 2007;56(2):91-8
28. Hsiao A, Worrall DS, Olefsky JM, Subramaniam S. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 2004;20(17):3108-27
29. Pai V, Paneerselvam A, Mukhopadhyay S, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol 2014;8(1):132-41
30. Jani RH, Pai V, Jha P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther 2014;16(2):63-71
31. Raval P, Jain M, Goswami A, et al. Revisiting glitazars: thiophene substituted oxazole containing a-ethoxy phenylpropanoic acid derivatives as highly potent PPARa/c dual agonists devoid of adverse effects in rodents. Bioorg Med Chem Lett 2011;21:3103-9
32. Lipaglyn product monograph, Saroglitazar, Zydus Discovery. Available from: http://lipaglyn.com/downloads/Lipaglyn-Product-Monograph.pdf [Accessed on 06 November 2014
33. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 2007;125:451-72
34. Karimi I. Animal models as tools for translational research: focus on atherosclerosis, metabolic syndrome and type-II diabetes mellitus. http://dx.doi. org/10.5772/47769 [Accessed on 06 November 2014
35. Jain MR, Giri SR, Sundar R, et al. ZYH1, a Novel PPAR Agonist that shows lipid-lowering and insulinsensitizing effects with good safety profile in preclinical models. Diabetes 2012;61(Suppl 1A):A269-70
36. Jani RH, Kansagra K, Jain MR, Patel H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARa agonist with moderate PPARg agonist activity in healthy human subjects. Clin Drug Investig 2013;33(11):809-16
37. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006;35:491-510
38. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: united Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316(7134):823-8
39. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
40. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29(6):1220-6
41. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685-96
42. Available from: http://ctri.nic.in/Clinicaltrials/pmaindet2.php?. trialid=1322&EncHid=&userName=saroglitazar [Accessed on 14 July 2014
43. Available from: http://ctri.nic.in/Clinicaltrials/pmaindet2.php?. trialid=1323&EncHid=&userName=saroglitazar [Accessed on 14 July 2014
44. Available from: http://ctri.nic.in/Clinicaltrials/pmaindet2.php?. trialid=6705&EncHid=&userName=saroglitazar [Accessed on 14 July 2014
45. Available from: http://ctri.nic.in/Clinicaltrials/pmaindet2.php?. trialid=9538&EncHid=&userName=saroglitazar [Accessed on 9 September 2014
46. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001;249:225-35
47. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008;371:1800-9
48. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very lowdensity lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-36
49. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 2005;366(9493):1279-89
50. Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013;30(9):1026-32
51. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone interim report of a longitudinal cohort study. Diabetes Care 2011;34(4):916-22
52. Kostapanos MS, Elisaf MS, Mikhailidis DP. Pioglitazone and cancer: angel or demon?. Curr Pharm Des 2013;19(27):4913-29
53. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
54. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71
55. Balas B, Belfort R, Harrison SA, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 2007;47:565-70
56. Ruano G, Bernene J, Windemuth A, et al. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin Chim Acta 2009;400:48-55
57. ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1563-74
58. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849-61
59. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 2009;32(3):493-8
60. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363(7):692-4
61. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014;371:32-41
62. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007;154(5):943-53
63. Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabtes mellitus. N Engl J Med 2010;362:1563-74
64. Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus the AleCardio randomized clinical trial. JAMA 2014;311(15):1515-25